BioSpace News Archive

The United States Food and Drug Administration has issued an emergency use authorization for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis.

As we transition into a Phase III company, we want to take the opportunity to highlight recent progress and to outline our strategy as we pursue monetization of our promising drug candidates and hydrogen sulfide platform.

The global market for high throughput process development is expected to grow alongside the biopharmaceutical industry.

The global fill-finish manufacturing market is anticipated to rise with a number of technological advancements witnessed in the recent time.

The global epigenetics market is expected to grow at a fast paced CAGR in the next few years, owing to factors such as extensive use in the research of developmental and disease process, and growing importance of Life Science.

The global efficacy testing market is anticipated to surge at a steady CAGR and is foreseen to be valued significantly by the end of the forecast period from 2017 to 2025.

A recent market research report by TMR Research covers the global market for biotechnology. The report is titled “Biotechnology Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017–2025.” The market is surging and is likely to continue to expand at a promising pace over the forecast period as well.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference.

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today preliminary results from two prospective studies demonstrated that AnPac Bio’s Cancer Differentiation Analysis (CDA) based tests have the ability to assess the risks of cancer occurrence. In a study of follow-up phone

~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~ ~ Company Expects to Report Top-Line Results from the Phase 3 LOGICS Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome in September 2020 ~ ~ Increased Cash Position and Extended Runway to Fund Operations Through the First Quarter of 2022 Following Completion of a $30 Million Debt Facility ~ ~ Appointed J